Zydus Sun Pharma Sign Licensing Agreement To Co Market Desidustat

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Zydus, Sun Pharma sign licensing agreement to co-market Desidustat

ri-calendar-2-lineOct 30, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

Zydus Lifesciences announced on Monday that it has signed an agreement with Sun Pharma to market an oral therapy drug for anaemia linked to chronic kidney disease (CKD) in the nation.

 

According to a regulatory filing from Zydus, the businesses have engaged into a licencing arrangement to co-market the novel medication, Desidustat, in India.

 

It said that Zydus has given Sun Pharma semi-exclusive rights to co-market the product in India under the terms of the agreement. It further stated that Sun Pharma will sell the medication under the Rytstat brand.

 

The medication was introduced by Zydus in 2022 under the brand name Oxemia, and it will still be sold domestically. As part of the deal, Zydus will receive upfront licensing income and is eligible to receive milestone income based on achievement of pre-defined milestones, the drug firm noted.

 

"The addition of Rytstat further strengthens our nephrology portfolio in India. This partnership will allow greater access to a critical therapy, helping millions of patients suffering from CKD," Sun Pharma CEO - India Business Kirti Ganorkar said.

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartCommodities

Why Gold Remains a Safe Haven Amid Global Economic Shifts in 2025

0 people read

4 mins read . Sep 5, 2025

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions